Evidence map›Paper›PMID 40517291›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Therapeutic effect of galactosyltransferase- and sialyltransferase-encoding mRNA in rheumatoid arthritis.

Xinyi Peng, Yingyu Li, Xiu Sun, Guoru Ren, Haojun Li, Xiaocheng Wang, Peng George Wang, Qingwen Wang, Yang Ji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinyi PengDepartment of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China; The Key Laboratory of Inflammatory and Immunology Diseases, Shenzhen 518036, China; Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Yingyu LiDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China; Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen 518055, China.
Xiu SunMedi-X Pingshan, Southern University of Science and Technology, Shenzhen 518000, China.
Guoru RenMedi-X Pingshan, Southern University of Science and Technology, Shenzhen 518000, China.
Haojun LiDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China; Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen 518055, China.
Xiaocheng WangDepartment of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China; The Key Laboratory of Inflammatory and Immunology Diseases, Shenzhen 518036, China.
Peng George WangDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China; Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen 518055, China. Electronic address: wangp6@sustech.edu.cn.
Qingwen WangDepartment of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China; The Key Laboratory of Inflammatory and Immunology Diseases, Shenzhen 518036, China. Electronic address: wqw_sw@163.com.
Yang JiDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China; Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen 518055, China. Electronic address: jiy@sustech.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycoengineering of IgG, particularly Fc glycosylation, holds significant promise for treating autoimmune diseases by modulating antibody effector functions. However, methods that precisely control IgG glycosylation profiles in vivo are still lacking. In this study, by delivering mRNAs encoding the glycosyltransferases B4GALT1 and ST6GAL1 intravenously, we successfully expressed functional enzymes and demonstrated therapeutic benefits in rheumatoid arthritis animal models in a platelet-dependent manner. We further verified that intra-articular administration effectively ameliorated collagen-induced arthritis in rats. Our findings demonstrate that IgG galactosylation and sialylation, modulated by mRNA drug technology, shift immune responses from pro-inflammatory to anti-inflammatory states, similar to the mechanisms of intravenous immunoglobulin (IVIG) therapies. This study establishes glycosyltransferase-encoding mRNA-LNP technology as a versatile platform for modulating in vivo IgG glycosylation and treating associated diseases.

Indexed as

Arthritis, RheumatoidGalactosyltransferasesRNA, MessengerSialyltransferasesAnimalsArthritis, ExperimentalDisease Models, AnimalGlycosylationHumansImmunoglobulin GMaleRatsGalactosyltransferasesImmunoglobulin GRNA, MessengerSialyltransferasesglycoengineeringIgG glycosylationmRNA technologymRNA therapyrheumatoid arthritissialic acid

Identifiers

PMID40517291
PMCPMC12432907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.